Condition
2019 Novel Coronavirus
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Withdrawn1
Suspended1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04731051Phase 1WithdrawnPrimary
The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
NCT05113810Phase 2UnknownPrimary
The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19
NCT04334967Phase 4Suspended
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
Showing all 3 trials